Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Guidelines for patient training and radiation protection for patients treated with radioactive iodine for thyroid cancer

2.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

3.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.

4.

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

5.

Q&A: When will individuals be able to receive customized cancer vaccines?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot